At some point – it could be sooner, it could be later – the U.S. Federal Reserve will “pull the plug”
on its “economic-stimulus/quantitative-easing/bond-buyback” program. And when it does, “it
will be   Read More

“We are now,” says editor Ray Blanco, “in the early stages of a huge change in how we treat cancer.” He believes that “serious progress” is being made in the   Read More

“Stocks that soar 178 per cent in six months don’t come along every day,” notes editor Chloe Lutts Jensen. But soar Invivo Therapeutics Holdings Corp. (NVIV-OTCBB, $4.22) did, with a   Read More

This advisory is dropping American Express Co. (AXP-NYSE, $75.64) from its “buy” list. Yes, its shares are yelling “charge it!” (they’re up 29 per cent this year) and running ahead   Read More

None of the latest data on U.S. housing starts and retail sales suggest that America’s recovery is slamming the door closed. But there are doubts among some observers about the   Read More

Optical component manufacturer LightPath Technologies Inc. (NASDAQ-LPTH) has its eye on the prize of three growing markets: glass aspheres (i.e., laser tools and gun sights), specialty optics (such as scientific   Read More

The latest data on U.S. housing starts and retail sales have caused doubts among some observers about the strength of the American economic recovery. In June, housing starts declined 9.9   Read More

At times we also offer tips on how to boost your returns above the posted rates, by negotiating, or through bonuses for re-upping at the same institution, or by switching   Read More

The shares of Pason Systems (TSX-PSI) have risen by 2.3 per cent since April of this year. That’s likely because it’s overpriced. We now downgrade Pason to a hold.

Pason trades   Read More